-+ 0.00%
-+ 0.00%
-+ 0.00%

CSPC Group announced that the second marketing license application for the simeglutide injection developed by Shiyao Group Baike Biopharmaceutical Co., Ltd., a subsidiary of the Company, has been accepted by the State Drug Administration of the People's Republic of China. The indication for this report is long-term weight management for adult overweight/obese patients based on diet control and increased physical activity. Previously, the marketing license application for this product intended for use in adult type 2 diabetes blood sugar control was accepted by the State Drug Administration in August 2025.

Zhitongcaijing·12/08/2025 09:49:05
Listen to the news
CSPC Group announced that the second marketing license application for the simeglutide injection developed by Shiyao Group Baike Biopharmaceutical Co., Ltd., a subsidiary of the Company, has been accepted by the State Drug Administration of the People's Republic of China. The indication for this report is long-term weight management for adult overweight/obese patients based on diet control and increased physical activity. Previously, the marketing license application for this product intended for use in adult type 2 diabetes blood sugar control was accepted by the State Drug Administration in August 2025.